US 8,252,526 · Application 11/983,482 · Granted Aug 28, 2012
US 8,252,526
Novel shrna molecules and methods of use thereof
Estimated expiration
November 17, 2026
48 days remaining
Earliest effective filing
Nov 17, 2006
+ 20 years
Nov 17, 2026
PTA +0d
Nov 17, 2026
No TD
—
Final
Nov 17, 2026
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- November 9, 2007
- Earliest effective filing
- November 17, 2006
- Issue date
- August 28, 2012
- PTA
- 0 days
- Base expiry (before PTA)
- November 17, 2026
November 17, 2006 + 20 years = November 17, 2026
- Continuation-in-part of application 11/601,431, filed Nov 17, 2006, issued as US 8,603,991
- PRO60/772,015 — Provisional — not used for base term
- PRO60/738,160 — Provisional — not used for base term
- PRO60/932,653 — Provisional — not used for base term
- PRO60/897,214 — Provisional — not used for base term
- PRO60/857,846 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/983,482 · US 8,252,526
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,252,526: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8252526Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.